Vaccine News and Research

Latest Vaccine News and Research

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal COVID-19 vaccine in mice.

11 May 2021

Case study describes consequences of undetected SARS-CoV-2 infection during mRNA vaccination

Now, a new report describes a case of a coincidental mRNA vaccination and SARS-CoV-2 infection in a 31-year-old doctor, addressing the theoretical considerations for potential risks and further required actions in case more cases appear in the future.

11 May 2021

The "key" to vaccine development depends on virus’ binding to human cells

New variants of the SARS-CoV-2 virus most likely will necessitate the development of more vaccine options in the years ahead, and a biomedical scientist at Iowa State University believes the "key" to that development lies in the way the virus binds to human cells.

11 May 2021

FDA expands emergency use authorization for Pfizer-BioNTech COVID-19 Vaccine

Today, the U.S. Food and Drug Administration expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age.

10 May 2021

FDA to convene virtual meeting to discuss pediatric use of COVID-19 vaccines

The following quote is attributed to Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.

10 May 2021

Natural products a rich source for novel antiviral compounds

In a recent review in the journal Viruses, researchers look at natural products that can be identified as potential alternative antiviral agents. The reviewers discussed the antiviral activities of several natural products towards DNA and RNA viruses with an analytical approach. The researchers detailed the cellular/viral targets of the active molecules and their impact on the infection and viral replication cycle.

10 May 2021

Lab reports 1st instance of SARS-CoV-2 variants affecting antigen test performance

Researchers from the US recently determined the sensitivity of the Quidel Sofia SARS Antigen FIA test (Sofia 2). They found a high viral load specimen that tested negative repeatedly while using this antigen test. The study is published on the preprint server, medRxiv.

10 May 2021

New spray protocol improves delivery of nasal antiseptic to reduce COVID-19 infection

A trip to visit family in Kolkata, India, put South Dakota State University assistant professor Saikat Basu in the middle of that country's second wave of COVID-19 infections.

10 May 2021

New vaccine shows potential to protect from a variety of coronavirus infections

A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections -- including SARS-CoV-2 as well as the original SARS-CoV-1 and related bat coronaviruses that could potentially cause the next pandemic.

10 May 2021

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Scientists produce a universal flu vaccine using nanoparticles to induce long-lasting immunity

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID)’s Vaccine Research Center (VRC) and the University of Washington School of Medicine’s Institute for Protein Design (IPD) developed a universal flu vaccine candidate using small particles (nanoparticles), which can induce a long-lasting immune response.

10 May 2021

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

In a recent study, researchers developed and validated a nanoimmunoassay (NIA) that analyzes 1,024 samples in parallel on a single microfluidic device the size of a USB stick. They detected anti-SARS-CoV-2 IgG antibodies, achieving a sensitivity of 98% and specificity of 100% based on an analysis of 134 pre-pandemic sera (collected in 2013/2014 and 2018) and 155 sera from reverse transcription-polymerase chain reaction (RT-PCR) positive individuals.

10 May 2021

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Now, in new research posted to the bioRxiv preprint server, scientists at Novavax, Inc. present a vaccine including recombinant influenza hemagglutinin (HA) antigen along with recombinant SARS-CoV-2 spike protein, with saponin Matrix-M adjuvant. Both have passed independent safety tests in phase 1 trials.

10 May 2021

New model could help test vaccines against the deadly Strep A bacteria

Researchers have successfully developed a new Strep A human challenge model, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores.

10 May 2021

Increased heart rate as a physiological response to SARS-CoV-2 mRNA vaccine

Although widely publicized, evidence for physiological responses to the vaccines is currently scarce in published literature. Giogiro Quer and Matteo Gadaleta of the Scripps Research Translational Institute in California, USA, led an investigation to obtain tracking data for physiological responses to vaccine programs.

8 May 2021

New research lays the groundwork for an effective salmonella vaccine

With the COVID-19 vaccines on many people's minds, some may be surprised to learn that we do not yet have vaccines for many common infectious diseases.

7 May 2021

Pfizer-BioNTech mRNA vaccine reduces both symptomatic and asymptomatic COVID-19 infection in case study

Follow-up of vaccinated and unvaccinated individuals at St. Jude Children’s Research Hospital revealed asymptomatic infection reduced by 90% and symptomatic infections reduced by up to 96% in vaccinated people compared to those not vaccinated.

7 May 2021

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

An interesting new study describes the emergence of several such variants from a chronically immunosuppressed COVID-19 patient, who remained infected for over 170 days before clearing the virus.

7 May 2021

Researchers report encouraging results from experimental antiviral targeting Marburg virus

The Marburg virus, a relative of the Ebola virus, causes a serious, often-fatal hemorrhagic fever. Transmitted by the African fruit bat and by direct human-to-human contact, Marburg virus disease currently has no approved vaccine or antivirals to prevent or treat it.

7 May 2021

Highly efficient immune response in asymptomatic SARS-CoV-2 patients

Researchers in Singapore have investigated the role of SARS-CoV-2-specific antibodies and T-cells in asymptomatic individuals suffering from COVID-19. They found that, contrary to some initial hypotheses, asymptomatic individuals mount an adaptive immune response on par with symptomatic individuals, demonstrating that T cell response does not appear to be correlated with symptom severity.

7 May 2021

Vaccine News and Research

Latest Vaccine News and Research

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

Case study describes consequences of undetected SARS-CoV-2 infection during mRNA vaccination

The "key" to vaccine development depends on virus’ binding to human cells

FDA expands emergency use authorization for Pfizer-BioNTech COVID-19 Vaccine

FDA to convene virtual meeting to discuss pediatric use of COVID-19 vaccines

Natural products a rich source for novel antiviral compounds

Lab reports 1st instance of SARS-CoV-2 variants affecting antigen test performance

New spray protocol improves delivery of nasal antiseptic to reduce COVID-19 infection

New vaccine shows potential to protect from a variety of coronavirus infections

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Scientists produce a universal flu vaccine using nanoparticles to induce long-lasting immunity

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

Combo COVID-flu vaccine protects against current and emerging variants in animal model

New model could help test vaccines against the deadly Strep A bacteria

Increased heart rate as a physiological response to SARS-CoV-2 mRNA vaccine

New research lays the groundwork for an effective salmonella vaccine

Pfizer-BioNTech mRNA vaccine reduces both symptomatic and asymptomatic COVID-19 infection in case study

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

Researchers report encouraging results from experimental antiviral targeting Marburg virus

Highly efficient immune response in asymptomatic SARS-CoV-2 patients

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in